About
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive disorders; and Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for treating cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for treating gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.
Key Metrics
as of Sep 2026Market Cap10,702 Cr
P/E—
Div Yield0.00 %
Book Value₹22.40
52w High₹403.00
52w Low₹124.00
Face Value₹1.00
Quarterly Results
Rs. Crores · hover row for definition| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.00 | 2.00 | 3.00 | 1.00 | 2.00 | 1.00 | 2.00 | 3.00 | 1.00 | 2.00 | 2.00 | 3.00 | 4.00 |
| Expenses | 136.00 | 52.00 | 106.00 | 81.00 | 53.00 | 45.00 | 41.00 | 55.00 | 32.00 | 33.00 | 49.00 | 27.00 | 32.00 |
| Operating Profit | -132.00 | -51.00 | -103.00 | -80.00 | -51.00 | -44.00 | -39.00 | -52.00 | -31.00 | -30.00 | -46.00 | -24.00 | -28.00 |
| OPM % | -3,711.00 | -3,331.00 | -3,678.00 | -8,671.00 | -2,714.00 | -2,981.00 | -2,435.00 | -2,032.00 | -3,024.00 | -1,267.00 | -1,885.00 | -768.00 | -737.00 |
| Other Income | 8.00 | 7.00 | 3.00 | 4.00 | 1.00 | 1.00 | 2.00 | 4.00 | 4.00 | 4.00 | 6.00 | 13.00 | 6.00 |
| Depreciation | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -128.00 | -46.00 | -102.00 | -77.00 | -52.00 | -44.00 | -39.00 | -50.00 | -28.00 | -28.00 | -42.00 | -13.00 | -24.00 |
| Tax % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | -128.00 | -46.00 | -102.00 | -77.00 | -52.00 | -44.00 | -39.00 | -50.00 | -28.00 | -27.00 | -42.00 | -13.00 | -24.00 |
| EPS in Rs | -4.83 | -1.73 | -4.48 | -3.40 | -2.36 | -2.01 | -1.79 | -2.28 | -1.29 | -1.22 | -1.91 | -0.58 | -1.10 |
Profit & Loss
Annual · Rs. Crores| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.00 | 7.00 | 12.00 | 14.00 | 12.00 | 13.00 | 13.00 | 286.00 | 625.00 | 543.00 | 499.00 | 521.00 |
| Expenses | 291.00 | 172.00 | 140.00 | 139.00 | 134.00 | 93.00 | 128.00 | 300.00 | 427.00 | 414.00 | 398.00 | 361.00 |
| Operating Profit | -284.00 | -166.00 | -128.00 | -126.00 | -122.00 | -80.00 | -116.00 | -14.00 | 198.00 | 129.00 | 102.00 | 159.00 |
| OPM % | -3,999.00 | -2,487.00 | -1,094.00 | -929.00 | -1,032.00 | -593.00 | -917.00 | -5.00 | 32.00 | 24.00 | 20.00 | 31.00 |
| Other Income | 14.00 | 11.00 | 29.00 | 14.00 | 5.00 | 8.00 | 14.00 | 27.00 | 23.00 | 21.00 | 19.00 | 9.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 2.00 | 5.00 | 6.00 | 6.00 | 5.00 |
| Depreciation | 6.00 | 6.00 | 6.00 | 7.00 | 4.00 | 4.00 | 4.00 | 11.00 | 21.00 | 21.00 | 18.00 | 12.00 |
| Profit before tax | -276.00 | -161.00 | -106.00 | -118.00 | -122.00 | -77.00 | -106.00 | 0.00 | 196.00 | 123.00 | 98.00 | 152.00 |
| Tax % | 0.00 | 0.00 | -1.00 | 0.00 | 0.00 | -7.00 | -11.00 | 15,038.00 | 37.00 | 29.00 | 26.00 | 28.00 |
| Net Profit | -276.00 | -161.00 | -105.00 | -118.00 | -122.00 | -72.00 | -94.00 | -24.00 | 124.00 | 87.00 | 72.00 | 109.00 |
| EPS in Rs | -10.48 | -7.37 | -4.82 | -5.42 | -5.59 | -3.78 | -4.94 | -1.25 | 6.48 | 4.57 | 3.76 | 5.70 |
| Dividend Payout % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -80.00 | 15.00 | 15.00 | 35.00 | 7.00 |
Balance Sheet
Annual · Rs. Crores — latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 26.00 | 22.00 | 22.00 | 22.00 | 15.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 |
| Reserves | 565.00 | 88.00 | 248.00 | 354.00 | 82.00 | 95.00 | 131.00 | 226.00 | 755.00 | 654.00 | 583.00 | 547.00 |
| Borrowings | 17.00 | 0.00 | 1.00 | 2.00 | 3.00 | 5.00 | 6.00 | 3.00 | 34.00 | 71.00 | 83.00 | 109.00 |
| Other Liabilities | 16.00 | 25.00 | 14.00 | 12.00 | 9.00 | 16.00 | 33.00 | 62.00 | 118.00 | 78.00 | 74.00 | 105.00 |
| Total Liabilities | 624.00 | 135.00 | 285.00 | 389.00 | 108.00 | 128.00 | 182.00 | 303.00 | 919.00 | 816.00 | 751.00 | 773.00 |
| Fixed Assets | 73.00 | 60.00 | 28.00 | 37.00 | 38.00 | 21.00 | 25.00 | 22.00 | 308.00 | 306.00 | 305.00 | 172.00 |
| CWIP | 4.00 | 0.00 | 0.00 | 0.00 | 4.00 | 5.00 | 0.00 | 0.00 | 25.00 | 10.00 | 7.00 | 107.00 |
| Investments | 181.00 | 22.00 | 76.00 | 46.00 | 45.00 | 0.00 | 0.00 | 223.00 | 279.00 | 301.00 | 0.00 | 0.00 |
| Other Assets | 367.00 | 53.00 | 181.00 | 305.00 | 22.00 | 103.00 | 157.00 | 58.00 | 308.00 | 199.00 | 439.00 | 494.00 |
| Total Assets | 624.00 | 135.00 | 285.00 | 389.00 | 108.00 | 128.00 | 182.00 | 303.00 | 919.00 | 816.00 | 751.00 | 773.00 |
Cash Flows
Annual · Rs. Crores — latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -300.00 | -155.00 | -115.00 | -116.00 | -128.00 | -96.00 | -135.00 | -53.00 | 70.00 | 109.00 | 68.00 | 143.00 |
| Cash from Investing Activity | -462.00 | 155.00 | 94.00 | -248.00 | -22.00 | 56.00 | 146.00 | 30.00 | -1.00 | -311.00 | -39.00 | -110.00 |
| Cash from Financing Activity | 757.00 | -1.00 | -1.00 | 396.00 | 146.00 | 35.00 | 3.00 | 5.00 | -52.00 | -30.00 | -68.00 | 179.00 |
| Net Cash Flow | -5.00 | -1.00 | -22.00 | 32.00 | -4.00 | -5.00 | 14.00 | -18.00 | 17.00 | -232.00 | -39.00 | 212.00 |
| Free Cash Flow | -305.00 | -193.00 | -113.00 | -119.00 | -147.00 | -102.00 | -137.00 | -92.00 | 28.00 | 79.00 | 10.00 | 25.00 |
| CFO/OP % | 106.00 | 93.00 | 95.00 | 91.00 | 104.00 | 119.00 | 114.00 | 262.00 | 57.00 | 111.00 | 93.00 | 113.00 |
Ratios
Annual · Days / % — latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 78.00 | 73.00 | 40.00 | 22.00 | 40.00 | 48.00 | 66.00 | 3.00 | 36.00 | 31.00 | 39.00 | 28.00 |
| Inventory Days | — | — | — | — | — | — | — | 0.00 | 329.00 | 222.00 | 183.00 | 165.00 |
| Days Payable | — | — | — | — | — | — | — | — | 134.00 | 91.00 | 78.00 | 89.00 |
| Cash Conversion Cycle | 78.00 | 73.00 | 40.00 | 22.00 | 40.00 | 48.00 | 66.00 | 3.00 | 231.00 | 162.00 | 144.00 | 105.00 |
| Working Capital Days | 506.00 | -440.00 | 101.00 | 265.00 | 234.00 | 1,084.00 | 704.00 | 23.00 | 82.00 | 42.00 | 55.00 | 49.00 |
| ROCE % | -80.00 | -87.00 | -36.00 | -53.00 | -118.00 | -58.00 | -54.00 | -4.00 | 24.00 | 15.00 | 13.00 | — |
Corporate Actions
33 records| Action | Ex Date | Record Date | Ratio | Amount (₹) | Notes |
|---|---|---|---|---|---|
| Other | 30 Jul 2024 | — | — | — | Annual General Meeting |
| Other | 02 Aug 2023 | — | — | — | Annual General Meeting |
| Rights | 17 Oct 2022 | 18 Oct 2022 | 1:2 | — | |
| Other | 17 Oct 2022 | 18 Oct 2022 | — | — | Right Issue of Equity Shares |
| Other | 29 Jul 2022 | — | — | — | Annual General Meeting |
| Other | 02 Aug 2021 | — | — | — | Annual General Meeting |
| Other | 11 Sep 2020 | — | — | — | Annual General Meeting |
| Other | 21 Jan 2020 | 22 Jan 2020 | — | — | Spin Off |
| Other | 21 Jan 2020 | 22 Jan 2020 | — | — | Demerger |
| Other | 08 Aug 2019 | — | — | — | Annual General Meeting |
| Dividend | 14 Feb 2019 | 15 Feb 2019 | — | 1.50 | |
| Other | 09 Aug 2018 | — | — | — | Annual General Meeting |
| Dividend | 06 Feb 2018 | 07 Feb 2018 | — | 1.50 | |
| Other | 09 Aug 2017 | — | — | — | Annual General Meeting |
| Dividend | 08 Feb 2017 | 09 Feb 2017 | — | 1.00 | |
| Other | 04 Aug 2016 | — | — | — | Annual General Meeting |
| Dividend | 14 Mar 2016 | 15 Mar 2016 | — | 1.00 | |
| Dividend | 23 Jul 2015 | — | — | 0.60 | |
| Dividend | 24 Jul 2014 | — | — | 2.00 | NSE/BSE dividend mismatch: BSE/NSE=0.5; BSE/NSE=2.0 |
| Dividend | 24 Jul 2014 | — | — | 0.50 | NSE/BSE dividend mismatch: BSE/NSE=0.5; BSE/NSE=2.0 |
| Dividend | 01 Aug 2013 | — | — | 0.30 | |
| Other | 01 Aug 2013 | — | — | — | Annual General Meeting / Dividend - Re.0.30/- Per Equity Share |
| Dividend | 17 Sep 2012 | — | — | 0.30 | |
| Dividend | 01 Aug 2011 | — | — | 0.25 | |
| Dividend | 19 Jul 2010 | — | — | 0.25 | |
| Dividend | 14 Sep 2009 | — | — | 0.25 | |
| Dividend | 11 Sep 2008 | — | — | 0.25 | |
| Dividend | 21 Sep 2007 | — | — | 0.25 | |
| Bonus | 23 Mar 2007 | 02 Apr 2007 | 1:1 | — | |
| Other | 23 Mar 2007 | 02 Apr 2007 | — | — | Fv Spl-Rs2 To Re1/Bon-1:1 |
| Dividend | 25 Sep 2006 | — | — | 0.50 | |
| Dividend | 05 Sep 2005 | — | — | 0.50 | |
| Dividend | 28 Sep 2001 | — | — | 4.00 |
Announcements
5 filingsShareholding Pattern
Open on BSEFinancial Results — Filings
Open on BSEBoard Filings
Open on BSEAnnual Reports
Credit Ratings
-
Rating update22 Apr 2020 from crisil
-
Rating update27 Jan 2020 from crisil
-
Rating update31 Dec 2019 from care
-
Rating update6 Nov 2019 from crisil
-
Rating update14 Oct 2019 from crisil
-
Rating update2 May 2019 from care